Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.39 |
| ▸ | PREP | P48147 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.35 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.35 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17318153 | 0.91 | CA12 (0.47) | ALDH1A1CA1CA12CA9PREP | |
| SCHEMBL14812000 | 0.90 | ALDH1A1 (0.41) | ALDH1A1CA1CA12CA9CYP1A1 | |
| SCHEMBL3544897 | 0.86 | CYP1A1 (0.42) | ALDH1A1CA1CA12CA9CYP1A1 | |
| SCHEMBL25665190 | 0.84 | RXRA (0.46) | CA1CA12CA9CA2 | |
| SCHEMBL5292779 | 0.84 | ACHE (0.45) | ALDH1A1CA1CA12CA9CA2 | |
| SCHEMBL28615509 | 0.82 | CA12 (0.37) | ALDH1A1CA1CA12CA9PREP | |
| SCHEMBL23723314 | 0.82 | CA12 (0.42) | CA1CA12CA9PREP | |
| SCHEMBL1594100 | 0.82 | CA1 (0.42) | CA1CA12CA9PREPCA2 | |
| SCHEMBL26763405 | 0.82 | CA12 (0.42) | ALDH1A1CA1CA12CA9PREP | |
| SCHEMBL3057447 | 0.82 | CA1 (0.50) | ALDH1A1CA1CA12CA9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140413-A1 | WATER-SOLUBLE TRIMETHOXYPHENYLPYRIDINE-TYPE COMPLEXING AGENTS, AND CORRESPONDING LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2020-05-07 | — | — | US | disclosed |
| US-10597409-B2 | Water-soluble triazapyridinophane-based complexing agents and corresponding fluorescent lanthanide complexes | CISBIO BIOASSAYS (FR) | 2020-03-24 | — | — | US | disclosed |
| US-8431603-B2 | 3-phenylpyrazolo[5,1-b]thiazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-30 | — | — | US | disclosed |
| US-8431603-B2 | 3-phenylpyrazolo[5,1-b]thiazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-30 | — | — | US | disclosed |
| US-8431603-B2 | 3-phenylpyrazolo[5,1-b]thiazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-30 | — | — | US | disclosed |
| EP-2266990-B1 | 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| EP-2266990-A1 | 3-PHENYLPYRAZOLOÝ5,1-b¨THIAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216330-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | disclosed |
| US-20090259049-A1 | 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20090259049-A1 | 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140413-A1 | WATER-SOLUBLE TRIMETHOXYPHENYLPYRIDINE-TYPE COMPLEXING AGENTS, AND CORRESPONDING LANTHANIDE COMPLEXES | RCC1, LASP1, POT1 | ALDH1A1 2585/4885CA1 315/4885CA12 841/4885 |
| US-10597409-B2 | Water-soluble triazapyridinophane-based complexing agents and corresponding fluorescent lanthanide complexes | GSTA1, CLIC1, SLC40A1 | ALDH1A1 390/4885CA1 856/4885CA12 1289/4885 |
| US-20090259049-A1 | 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS | CRHR1, AGTR1, CRHR2 | ALDH1A1 1071/4885CA1 1949/4885CA12 2668/4885 |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | GPR119, GLP1R, GPR4 | ALDH1A1 2370/4885CA1 4452/4885CA12 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.